Correction.

IF 1.4 4区医学 Q4 PHARMACOLOGY & PHARMACY Medical Letter on Drugs and Therapeutics Pub Date : 2023-11-13 DOI:10.58347/tml.2023.1689d

引用次数: 0

Abstract

In our article in issue 1687 on the updated 2023-2024 COVID-19 vaccines from Pfizer and Moderna (Med Lett Drugs Ther 2023; 65:161), the doses and formulations of the Pfizer vaccine were incorrect. A revised table has been posted in the online version of the article.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

修正。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Medical Letter on Drugs and Therapeutics 医学-药学

CiteScore

1.00

自引率

42.10%

发文量

审稿时长

6-12 weeks

期刊介绍： The Medical Letter, Inc. is committed to providing objective, practical, and timely information on drugs and treatments of common diseases to help our readers make the best decisions for their patients—without the influence of the pharmaceutical industry. The Medical Letter On Drugs and Therapeutics is a biweekly publication that provides: Evidence-based, peer-reviewed evaluations of new FDA-approved drugs with conclusions reached by a consensus of experts New information on previously approved drugs including pivotal clinical trials, new indications, and safety warnings Consensus recommendations for the preferred and alternative treatments for common disorders Comparative reviews of drugs for a given indication with particular attention to clinical efficacy, adverse effects, drug interactions, and cost.

期刊最新文献

In brief: Optune Pax - a portable device for pancreatic cancer. In brief: Ranitidine returns. Etripamil nasal spray (Cardamyst) for paroxysmal supraventricular tachycardia. In brief: A bumetanide nasal spray (Enbumyst) for edema. In brief: Rybelsus R2 rebranded as Ozempic.